Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd versus investigator's choice chemotherapy in previously treated HR-positive, HER2-negative metastatic breast cancer
2020-005620-12Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan in breast cancer and hormone receptor-positive/HER2-negative breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Objective response rate. Started Oct 2021; status: active.
02
Drugs
datopotamab deruxtecan
03
Conditions
breast cancerhormone receptor-positive/HER2-negative breast cancer
Beyond the preview
Go deeper on 2020-005620-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005620-12.